Page 3 | Certara

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

CertaraMay 7, 2026

Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

CertaraMay 7, 2026

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

CertaraMay 7, 2026

Press Release

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

LAVAL, Québec, and Radnor, PA — May 7, 2026 — Altasciences, a fully integrated drug…

CertaraMay 7, 2026

On-Demand Webinar

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

Explore how Phoenix NLME and RsNLME support early phase clinical pharmacology workflows where speed, clarity,…

CertaraMay 6, 2026

Press Coverage

The one-trial era: what the FDA’s shift signals for the future of drug development

The FDA is shifting toward approving drugs based on a single pivotal trial supported by…

CertaraMay 6, 2026

Blog

The Psychedelic Executive Order and the New U.S. Push on Psychedelic Research And What It Actually Means for Scientists

Learn how the Psychedelic Executive Order is shaping the U.S. push on psychedelic research, accelerating…

CertaraMay 5, 2026

Blog

How Pharma Can Transition to Non-animal Studies for Investigational Drugs

Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…

CertaraMay 5, 2026

Publication

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

QSP modeling reveals how anti-amyloid therapies impact tau biomarkers and cognitive outcomes in Alzheimer’s disease.

CertaraMay 4, 2026

Poster

Modeling CAR-T Outcomes in Multiple Myeloma

Learn how QSP modeling predicts CAR-T therapy outcomes, identifies patient-specific response drivers, and supports multi-antigen…

CertaraMay 4, 2026

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

The one-trial era: what the FDA’s shift signals for the future of drug development

The Psychedelic Executive Order and the New U.S. Push on Psychedelic Research And What It Actually Means for Scientists

How Pharma Can Transition to Non-animal Studies for Investigational Drugs

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

Modeling CAR-T Outcomes in Multiple Myeloma

Newsletter sign up

Quick links

Solutions

Contact